Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteiTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
In its October 2, 2026, Pharmalittle roundup, STAT reported four developments: 10 drugmakers approved for a 340B rebate pilot, an obesity-drug result that the newsletter framed as disappointing, expected departures from key Senate committees, and a Novartis licensing deal with China’s Abogen. The reports raise questions about drug pricing, clinical prospects and health-policy oversight, but the accessible coverage does not establish every underlying program, trial or contract detail.
What the 340B drug pilot changes—and what remains unclear
STAT reported that U.S. authorities approved 10 drugmakers to participate in a pilot that allows rebates instead of upfront discounts for certain providers in the 340B drug-pricing program. That is the core reported change; the roundup does not identify all participating manufacturers or specify which products and provider types are covered.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Obesity: Pathogenesis, Diagnosis, and Treatment (Endocrinology) | $373.15 | Buy on Amazon |
| 2 |
|
The ASMBS Textbook of Metabolic and Bariatric Surgery | $219.99 | Buy on Amazon |
| 3 |
|
Metabolic Syndrome: A Comprehensive Textbook | $224.21 | Buy on Amazon |
| 4 |
|
Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume Set | $367.94 | Buy on Amazon |
| 5 |
|
Practical Guide to Obesity Medicine | $99.99 | Buy on Amazon |
The accessible account also does not explain how rebates will be calculated or paid, when the pilot will begin, what administrative steps providers must take, or how the program will be evaluated. Those details matter for understanding the practical effect on participating providers, so the approval count alone does not establish how the pilot will work day to day.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Why the obesity-drug result was called disappointing
STAT relayed Bloomberg News’s report that an investigational obesity drug from Boehringer Ingelheim and Zealand Pharma helped patients with diabetes lose as much as 13.1% of their body weight. The result was described as disappointing in the context of a market led by Eli Lilly and Novo Nordisk. That is a market assessment in the roundup, not a clinical conclusion that the medicine lacks value.
#1 Best Overall
The accessible coverage does not provide the trial’s treatment duration, comparator, detailed patient population, statistical uncertainty, discontinuation rates, adverse events or changes in fat versus lean mass. Without those details, the top-line percentage cannot support a full comparison with other obesity medicines.
Boehringer’s position, as paraphrased by STAT, is that future heart and liver studies could show additional value. Those studies may address benefits beyond weight loss, but the roundup does not report their results.
Senate committee turnover could shape health-policy oversight
STAT reported that five or more of the 14 Republicans on the Senate Finance Committee were expected to leave the panel. It also reported that Senator Bill Cassidy, chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee, was departing.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Departures can change a committee’s membership and direction even if the party holding the Senate majority does not change. The midterm election outcome could also change which party controls committees. The report describes expected turnover, not final post-election assignments or a specific policy outcome.
Rank #3
Novartis’s reported licensing agreement with Abogen
STAT reported that Novartis signed a licensing agreement with Chinese biotechnology company Abogen described as worth about $7.8 billion. Under the terms summarized by STAT, Novartis receives exclusive rights to experimental RNA therapy ABO2203, which targets B cells and is being developed for autoimmune diseases including lupus and rheumatoid arthritis. The agreement also includes options related to additional Abogen RNA-based therapies.
The roundup does not provide a complete breakdown of the reported value or the agreement’s other financial terms. The figure should therefore be understood as STAT’s reported valuation, not as a fully itemized account of payments or obligations.
Quick Recap
Best Value
Rank #4
- Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume Set
- Product type: ABIS BOOK
- Brand: Elsevier
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Recommended Free Tools
